Skip to Contents

Long-acting platform technology

Protein/peptide therapeutics should be administered frequently due to their short half-lives, causing inconvenience to patients.
We are focusing on improving therapeutic efficacy and patients’ quality of life by adopting various long-acting platform technologies that can be tailored for each individual biotherapeutics.
Hanmi’s unique technology to prolong the duration of drug action using flexible linkers that connect aglycosylated Fc and therapeutic agents
Fc fusion
Long-acting technology that extends the duration of the therapeutic efficacy by fusing therapeutic drugs to the Fc fragment using recombination DNA technology
Long-acting technology for therapeutic peptides using fatty acid which bind to human albumin to reduce renal clearance.